Skip to main content
ENANTA PHARMACEUTICALS INC logo

ENANTA PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · ENTA ISIN · US29251M1062 LEI · 529900SSN4DODDQSN594 US Manufacturing
Filings indexed 812 across all filing types
Latest filing 2026-02-05 Major Shareholding Noti…
Country US United States of America
Listing US ENTA

About ENANTA PHARMACEUTICALS INC

https://www.enanta.com/

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule drugs, with a focus on virology and immunology. The company utilizes a robust, chemistry-driven approach to create novel oral therapeutics for diseases with high unmet medical needs. Enanta has a significant track record of success, having developed protease inhibitors that are key components of treatment regimens for chronic hepatitis C virus (HCV) infection, which have cured over one million patients. Its current clinical pipeline is primarily focused on developing treatments for respiratory syncytial virus (RSV) and advancing its immunology programs for inflammatory diseases.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-05 English
ARS Filing
Annual Report
2026-01-26 English
DEF 14A Filing
Proxy Solicitation & Information Statement
2026-01-26 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-01-20 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2025-12-05 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2025-12-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.